Difference between revisions of "Craniopharyngioma"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m (→References) |
||
| Line 42: | Line 42: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''Alliance A071601:''' Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. | + | # '''Alliance A071601:''' Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. [https://doi.org/10.1056/nejmoa2213329 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37437144/ PubMed] [https://clinicaltrials.gov/study/NCT03224767 NCT03224767] |
| − | [https://doi.org/10.1056/nejmoa2213329 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37437144/ PubMed] [https://clinicaltrials.gov/study/NCT03224767 NCT03224767] | ||
[[Category:Craniopharyngioma regimens]] | [[Category:Craniopharyngioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] | ||
Revision as of 00:52, 8 August 2023
1 regimens on this page
1 variants on this page
|
Guidelines
NCCN
- NCCN does not have guidelines at this granular level; please go to the Central Nervous System Cancers category page.
All lines of therapy
Cobimetinib & Vemurafenib
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Brastianos et al. 2023 (Alliance A071601) | NR in abstract | Phase 2 |
Eligibility criteria
- Histology: Papillary
Biomarker eligibility criteria
- BRAF mutation
References
- Alliance A071601: Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. link to original article PubMed NCT03224767